PubMed Health⌕ Search

Biomedical subjects

J Fontcuberta

Publications and source records attributed to J Fontcuberta.

162 records · Page 9Linked to original sources
PubMed1985

[Severe early-onset thrombopenia induced by non-fractionated heparin: therapeutic trial with low molecular weight heparin].

A case of severe thrombocytopenia (27 x 10(3)/mm3) of early onset during unfractionated heparin (Héparine sodique Rovi) treatment is reported in a 75 year-old man suffering from a deep vein thrombosis of the right calf. It was not associated with thromboembolic or haemorrhagic complications. A serum heparin-dependent aggregating factor was not detected. Substitution of low molecular weight heparin (Choay Laboratory, CY 222, PM 4 500, 25 000 U anti-Xa/ml) for unfractionated heparin resulted in a progressive normalisation of the platelet count and improvement of the venous thrombosis.

Aged↗
PubMedDate not supplied

Late hemorrhagic disease of the newborn as a cause of intracerebral bleeding.

We report a case of a 4-week-old female who presented with late hemorrhagic disease of the newborn (HDN). The newborn was previously healthy, and she received 1 mg of intramuscular vitamin K at birth. She was exclusively breast-fed. At 4 weeks she began bleeding at the umbilicus and 4 days after she suffered an intracranial hemorrhage. Coagulation studies showed a deficiency of vitamin K-dependent coagulation factors, and the normalization of all clotting studies after administration of vitamin K confirmed the diagnosis of HDN. Our conclusions are that physicians must be alert to mild bleeding in newborns and that prophylaxis with 1 mg of intramuscular vitamin K at birth may be insufficient to prevent late HDN.

Age of Onset↗
PubMedDate not supplied

[Indications for the use of platelets, plasma and anti-hemorrhagic drugs].

During the last years, the use of hemoderivatives has largely increased. Their use carries a high risk for post-transfusion reactions and for transmission of severe infectious diseases. In a high percentage of cases the use of these compounds is inadequate. At the present time there are pharmacologic (desmopressin, antifibrinolytics, vitamin K) and nonpharmacologic strategies (autotransfusion, hemodilution, intra and postoperative recovery of blood) directed to avoid or to decrease the need for transfusion. We review all these strategies and we propose some criteria for transfusion of plasma and platelets, as well as attitudes for particular situations.

Antifibrinolytic Agents↗
PubMedDate not supplied

[Plasminogen depletion and incorporation in experimental venous thrombosis].

The objective of this piece of work is to study (using animals): venous thrombosis, the depletion and incorporation of plasminogen in thrombus of different stages of time, in order to devise better guide lines for the treatment of thrombosis than the conventional treatment. The studies relating to the plasminogen content of the thrombus show us that, on experimental venous thrombosis, as from the fifth day after which it occurred, the content of the plasminogen thrombus is reduced considerably. This data underlines the fact some venous thrombosis of over five days are resistant to conventional thrombolytic treatment. In relation to this we have to report that the mean lifespan according to our experiments of the plasminogen on beagle dogs is approximately sixteen hours. On the other hand the study of the addition of 125Lis-plasminogen, on experimental thrombosis of different stages of oldness show us that the above addition results in a 54% intake into the thrombus on three day, old thrombosis and 17% on five day old thrombosis. In conclusion we can suggest that the resistance to conventional thrombolytic treatment of old venous thrombosis (5-7 days old) is probably due to a reduction of efficiency of the thrombus plasminogen. At the same time the contribution of exogenous lis-plasminogen does not produce a sufficient enrichment of the thrombus in plasminogen. Therefore the therapeutic exogenous plasminogen addition is not advisable for relatively old thrombosis (less than or equal to 5 days old).

Animals↗
PubMedDate not supplied

Prophylaxis of thromboembolic disease with RO-11 (ROVI), during abdominal surgery. EMRO1 (Grupo Fstudio Multicintrico RO-11).

BACKGROUND/AIMS: We carried out a prospective, multicenter, double-blind, controlled and randomized trial, in two groups of patients (n = 100 each) with a low/moderate risk of Deep vein thrombosis (DVT), who underwent elective abdominal surgery. The aim of the study was to evaluate the efficacy and safety of RO-11 at a daily s.c. dose of 2,500 anti-FXa IU, compared with s.c. 5,000 IU of calcium unfractionated heparin (UH). MATERIAL AND METHODS: The endpoints for efficacy were the reduction of the frequency of DVT and Pulmonary embolism (PE). Safety was assessed by means of major and minor bleeding complications, allergy and thrombocytopenia < or = 50,000/mm3. RO-11 is a low molecular mass heparin (LMMH) (3,600 Da). RO-11 at a s.c. dose of 2,500 anti F-Xa IU combined with placebo experimental group (EG), was compared to 5,000 anti F-Xa IU of s.c. UH 12 hourly control group (CG), for 7 days. RESULTS: There were no cases of DVT, PE or death in any group. The requirement of transfusion, re-operation because of bleeding, and the frequency of wound hematoma were higher in the CG. The size of the wound hematoma was similar but tended to be larger in the CG. The number and size of hematoma at the injection site were higher in the CG. The mean anti F-Xa levels in the EG were similar throughout the treatment. One patient (EG) showed a moderate thrombocytopenia without thrombosis or bleeding. CONCLUSION: RO-11 at a single s.c. dose of 2,500 anti F-Xa IU is as efficient as, and safer than, UH in the prevention of thrombosis or related to abdominal surgery.

Abdomen↗